Holen Sie sich die Stockscreener-App
2.96
3.27%
-0.10
Handel nachbörslich:
2.99
0.03
+1.01%
Schlusskurs vom Vortag:
$3.06
Offen:
$3.08
24-Stunden-Volumen:
4.45M
Relative Volume:
1.23
Marktkapitalisierung:
$452.94M
Einnahmen:
$2.80M
Nettoeinkommen (Verlust:
$-115.18M
KGV:
-3.4934
EPS:
-0.8473
Netto-Cashflow:
$-94.03M
1W Leistung:
+7.25%
1M Leistung:
+24.37%
6M Leistung:
-21.28%
1J Leistung:
+29.82%
1-Tages-Spanne:
$2.96
$3.215
1-Wochen-Bereich:
$2.815
$3.285
52-Wochen-Spanne:
$2.0105
$5.228
Absci Corp Stock (ABSI) Company Profile
Firmenname
Absci Corp
Sektor
Branche
Telefon
(360) 949-1041
Adresse
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
2.96 | 468.25M | 2.80M | -115.18M | -94.03M | -0.8473 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-02 | Eingeleitet | JP Morgan | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-01-22 | Eingeleitet | Needham | Buy |
| 2024-10-02 | Eingeleitet | Guggenheim | Buy |
| 2024-07-03 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-07-18 | Eingeleitet | Truist | Buy |
| 2022-03-02 | Fortgesetzt | Cowen | Market Perform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-11-10 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-08-16 | Eingeleitet | BofA Securities | Neutral |
| 2021-08-16 | Eingeleitet | Cowen | Market Perform |
| 2021-08-16 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-16 | Eingeleitet | Stifel | Hold |
Alle ansehen
Absci Corp Aktie (ABSI) Neueste Nachrichten
Absci, DigitalOcean and other big stocks moving lower in Wednesday's pre-market session - MSN
Absci: Compelling AI Biotech Story, but Weak Fundamentals and Bearish Structure - investing.com
Highs Report: Can Absci Corporation lead its sector in growth2026 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Update Recap: Is Absci Corporation a top pick in the sectorWeekly Trade Summary & Stock Timing and Entry Methods - baoquankhu1.vn
Is now the right time to enter Absci CorporationQuarterly Growth Report & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Targets Report: Will Absci Corporation benefit from government policy2026 Weekly Recap & Weekly High Potential Stock Alerts - baoquankhu1.vn
Insider Trends: Will Absci Corporation benefit from government policy2026 Breakouts & Safe Entry Trade Signal Reports - baoquankhu1.vn
Absci Corp. Earnings Call: Betting on ABS-201 - tipranks.com
Redmile Group (ABSI) reports 5.4% Absci stake as share count rises - Stock Titan
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
Vanguard affiliates to report separately as ABSI holdings shift (ABSI) - Stock Titan
Here's Why We're Watching Absci's (NASDAQ:ABSI) Cash Burn Situation - finance.yahoo.com
What is HC Wainwright's Forecast for Absci FY2030 Earnings? - marketbeat.com
Absci price target lowered to $4.20 from $4.32 at Morgan Stanley - TipRanks
A Quick Look at Today's Ratings for Absci Corp(ABSI.US), With a Forecast Between $4.2 to $8 - 富途牛牛
Absci Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Absci (NASDAQ:ABSI) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Needham Reiterates Buy Rating on ABSI with Price Target of $7.00 - gurufocus.com
Absci Shares Fall on Wider 4Q Loss, Lower Revenue - news.futunn.com
Why Blaize Holdings Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
Absci Reports Positive ABS-201 Clinical Progress, Strong Financials, and Advances AI-Designed Therapeutics Pipeline in 2025 Results - Minichart
Absci Corp (ABSI) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience By GuruFocus - Investing.com Canada
TD Cowen Maintains Absci Corp(ABSI.US) With Buy Rating - Moomoo
Absci reports Q4 EPS (20c), consensus (17c) - TipRanks
Absci’s AI-Native Integrated Drug Creation Platform: Advancing Antibody Therapeutics and Biopharma Innovation - Minichart
Absci Corporation (ABSI) reports Q4 loss, misses revenue estimates - MSN
Absci Corp’s 2025 Q4 Call: FDA Delays, Oncology Partnership Shifts, and ABS-201 Timeline Contradictions - Bitget
Absci Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Absci’s Q4 2025 earnings miss forecasts, stock dips - Investing.com
Absci Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Absci Corp. (NASDAQ:ABSI) Reports Mixed Q4 Results Amid Clinical Progress - ChartMill
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Absci (NASDAQ: ABSI) deepens 2025 loss while pushing ABS-201 toward key data - Stock Titan
Absci earnings missed by $0.02, revenue fell short of estimates - Investing.com
Absci (NASDAQ:ABSI) Announces Quarterly Earnings Results - MarketBeat
Absci shares slip nearly 4% on Q4 revenue miss, wider loss than expected - Investing.com
Absci 10-K: Partner revenue $2.8M, Net loss $115.2M, EPS $(0.84) - TradingView
ABSCI ($ABSI) Releases Q4 2025 Earnings - Quiver Quantitative
Absci (NASDAQ: ABSI) highlights ABS-201 trial progress and AI drug platform - Stock Titan
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results - globenewswire.com
AbSci Corp options imply 13.4% move in share price post-earnings - TipRanks
Absci forms advisory board for endometriosis drug program - investing.com
Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic - The Manila Times
Absci forms advisory board for endometriosis drug program By Investing.com - Investing.com Canada
Absci taps Yale, Mayo experts for non-hormonal endometriosis drug - Stock Titan
Earnings Scheduled For March 24, 2026 - Benzinga
Earnings To Watch: Absci Corp (ABSI) Reports Q4 2025 Result - gurufocus.com
Finanzdaten der Absci Corp-Aktie (ABSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Absci Corp-Aktie (ABSI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pangalos Menelas N | Director |
Feb 27 '26 |
Buy |
2.74 |
75,095 |
205,760 |
189,055 |
| McClain Sean | Chief Executive Officer |
Feb 23 '26 |
Option Exercise |
1.21 |
396,399 |
479,643 |
8,730,966 |
| McClain Sean | Chief Executive Officer |
Feb 02 '26 |
Sale |
2.99 |
26,761 |
80,015 |
8,334,567 |
| Jonasson Zachariah | CFO / CBO |
Feb 02 '26 |
Sale |
2.99 |
17,496 |
52,313 |
383,538 |
| VAN HOUTEN FRANS | Director |
Dec 05 '25 |
Buy |
3.72 |
40,000 |
148,800 |
63,320 |
| Pangalos Menelas N | Director |
Sep 22 '25 |
Buy |
2.66 |
95,785 |
254,788 |
113,960 |
| Bedrick Todd | SVP, CAO |
Sep 22 '25 |
Buy |
2.70 |
10,000 |
27,000 |
180,428 |
| Busch Andreas | Chief Innovation Officer |
Jul 28 '25 |
Buy |
3.04 |
50,000 |
152,000 |
327,264 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):